Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome compared with COMBINATIONS: e. HALOPERIDOL + RISPERIDONE (low certainty).
1 finding from 1 review
Specific adverse events · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: specific compared with COMBINATIONS: e. HALOPERIDOL + RISPERIDONE (low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep compared with COMBINATIONS: h. RISPERIDONE + CLONAZEPAM (very low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome compared with COMBINATIONS: h. RISPERIDONE + CLONAZEPAM (low certainty).
1 finding from 1 review
Adverse effects · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects compared with COMBINATIONS: h. RISPERIDONE + CLONAZEPAM (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquilisation or asleep Not asleep · patients with psychosis‐induced aggression or agitation
HALOPERIDOL probably leads to lower tranquillisation or asleep ‐ not asleep compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (moderate certainty).
1 finding from 1 review
Repeated need for rapid tranquillisation ‐ needing additional benzodiazepine · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in repeated need for rapid tranquillisation ‐ needing additional… compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review
Specific behaviours ‐ agitation >50% reduction in PANSS‐EC score · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in specific behaviours ‐ agitation >50% reduction in PANSS‐EC score compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review
Global outcome ‐ rated as severe ‐ CGI‐S · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ rated as severe ‐ CGI‐S compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ EPS during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: Specific ‐ EPS during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (low certainty).
1 finding from 1 review
Adverse effects: specific ‐ acute dystonia · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ acute dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: h. RISPERIDONE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · patients with schizophrenia
1 finding from 1 review
Leaving the study early ‐ due to adverse effects (short term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to adverse effects ‐ short term (up to 6… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
No significant clinical response ‐ short term (up to 6 months) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in no significant clinical response ‐ short term (up to 6 months) compared with RISPERIDONE (low certainty).
1 finding from 1 review